BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
March 01 2022 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU)
(“BELLUS Health” or the “Company”), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of refractory chronic cough (“RCC”) and other cough
hypersensitivity indications, today announced that Roberto Bellini,
BELLUS Health's President and Chief Executive Officer, will
participate in a panel at the Cowen & Co. 42nd Annual Health
Care Conference.
Panel Details: Event: Cowen & Co. 42nd Annual Health
Care Conference Title: Respiratory/Infections Panel
Date/Time: Tuesday, March 8th, 2022 at 2:10 p.m. ET
A webcast of the panel discussion may be accessed on the Events
& Presentations page under the Investors & Media section of
BELLUS Health's website at www.bellushealth.com. Following the
event, an archived webcast will be available on the Company’s
website.
About BELLUS Health (www.bellushealth.com) BELLUS
Health is a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of RCC and other cough
hypersensitivity indications. The Company's product candidate,
BLU-5937, has successfully completed a Phase 2b trial in RCC.
BELLUS is planning a Phase 3 program, which is expected to begin in
the second half of 2022.
RCC is a cough lasting more than 8 weeks despite appropriate
treatment for underlying condition(s). It is estimated that there
are approximately 9 million patients in the United States suffering
from RCC. RCC is associated with significant adverse physical,
social, and psychosocial effects on health and quality of life.
Currently, there is no specific therapy approved for RCC and
treatment options are limited.
The Company is exploring the potential use of BLU-5937 in other
patient populations experiencing cough hypersensitivity as well as
other P2X3-related hypersensitization conditions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220301005476/en/
Ramzi Benamar Chief Financial Officer
rbenamar@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Nov 2024 to Dec 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Dec 2023 to Dec 2024